Practice and exploration of clinical pharmacists participating in refined pharmaceutical management of oncology center from the perspective of DRG
- VernacularTitle:DRG视角下临床药师参与肿瘤中心药事精细化管理的实践与思考
- Author:
Yuanlin WU
1
;
Qiuwan XIAN
2
;
Chen LI
1
;
Shigeng CHEN
3
;
Min HOU
1
;
Xiaofeng LUO
1
;
Yao LIU
1
Author Information
1. Dept. of Pharmacy，Daping Hospital，Army Medical University，Chongqing 400042，China
2. Medical Office，Medical Research Department，Daping Hospital，Army Medical University，Chongqing 400042，China
3. Medical Insurance Office，Medical Research Department，Daping Hospital，Army Medical University，Chongqing 400042，China
- Publication Type:Journal Article
- Keywords:
diagnosis related groups;
clinical pharmacist;
refined pharmaceutical management;
oncology center;
effectiveness
- From:
China Pharmacy
2022;33(22):2801-2806
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To investigate the effectiveness of clinical pharmacists’ participation in the refined pharmaceutical management for inpatients of oncology center based on diagnosis related groups （DRG）. METHODS Patients who entered DRG and stayed in hospital for less than 60 days in oncology center of Daping Hospital， Army Medical University were selected as the research objects to analyze the changes of DRG indicators and related hospitalization indicators before the intervention of clinical pharmacists’ participation in the refined pharmaceutical management （Jan.-Dec. 2019）， the first year after the intervention （Jan.- Dec. 2020）， and the second year after the intervention （Jan.-Dec. 2021）； the key DRG groups were selected from the oncology center according to DRG enrollment and disease diagnosis and treatment methods， and related hospitalization indicators before and after the intervention and rational drug use after intervention were analyzed. RESULTS Compared with before intervention， in the first and second years after the intervention， the number of DRG groups increased to 157 and 184， and the case mix index increased significantly （P＜0.05）， while costconsumption index， time consumption index， average hospital stay and average hospitalization expense per time were decreased or shortened significantly （P＜0.05）； drug cost per time was increased significantly （P＜0.05）， and there were no low- risk deaths and severe adverse drug reactions. Among the 4 key DRG groups， the average hospital stay in RE19 disease group and RU29 disease group in the first and second year after intervention and those of RU14 disease group in the first year after intervention were significantly lower than before （P＜0.05）； the average hospitalization expense per time of RE19 disease group in the first and second year after intervention and those of RU14 disease group， RV19 disease group and RU29 disease group in the second year after intervention were significantly lower than before （P＜0.05）； drug cost per time of RU14 disease group in the second year after intervention was significantly lower than before， while those of RE19 disease group and RU29 disease group in the first and second year after intervention were significantly higher than before （P＜0.05）. There was some irrational drug use in the DRG disease groups with a significant increase in the drug cost per time after the intervention， such as inappropriate selection of drugs， inappropriate usage and dosage， off-label drug use， etc. CONCLUSIONS In the context of DRG， after the clinical pharmacists participated in the refined pharmaceutical management， the overall diagnosis and treatment service capacity of oncology center are improved， the efficiency of diagnosis and treatment are improved， and there are no low-risk deaths and severe adverse drug reactions， which promote the management of rational drug use in medical institutions.
